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Abstract. Novel adamantane-containing β-amino acid, 2-(adamant-2-yl)-3-aminopropanoic acid,  
interesting from the aspect of medicinal chemistry, was prepared and characterized. It was synthesized in 
a sequence of three steps with very good overall yield. In the first step ethyl adamant-2-
ylidenecyanoacetate was prepared and its crystal structure was determined. Reduction of this unsaturated 
cyanoacetate by catalytic hydrogenation gave the ethyl ester of the desired amino acid. 2-(Adamant-2-yl)-
3-aminopropanoic acid was obtained following ester hydrolysis. (doi: 10.5562/cca2122)  
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INTRODUCTION 
The adamantyl group is present in seven compounds in 
current clinical use for the treatment of neurodegenera-
tive disorders, viral infections and type 2 diabetes, and 
in many more substances that are in development as 
potential therapeutics.1 In many cases the adamantyl 
group has been found to improve pharmacological 
properties of a parent compound, without increasing its 
toxicity. Incorporation of a bulky lipophilic adamantyl 
moiety into compounds increases their biological avail-
ability by inducing greater membrane permeability 
and/or decreasing the susceptibility to hydrolytic  
enzymes (amidases, esterases).2–5 
Adamantyl-containing compounds are utilized for 
a number of applications in medicinal chemistry. One of 
the applications is the modification of biologically  
active peptides, such as neuropeptides (enkephalines, 
vasopresins)6–8 and immunologically active muramyl 
dipeptides,9,10 by using amino acids containing the  
adamantane moiety. On the other hand, preparation of 
artificial peptides is useful for the study of peptide-
receptor interactions since the unnatural amino acids 
cause modifications in the peptide conformation. Espe-
cially interesting are those featuring bulky substituents, 
such as adamantyl, which cause the decrease of confor-
mational mobility of peptides.11−13 Adamantylglycines 
(with adamant-1-yl and adamant-2-yl substitents),14,15  
2-aminoadamantane-2-carboxylic acid,16 γ-aminoada-
mantane carboxylic acid17 are adamantane-containing 
amino acids used for these purposes.  
As a part of the project directed towards the prepa-
ration of adamantyl desmuramyldipeptides we report 
here an efficient synthesis of novel adamantane-based 
β-amino acid, 2-(adamant-2-yl)-3-aminopropanoic acid. 
Since relatively small changes in the primary structure 
of adamantyl desmuramyldipeptides (linkage of the 
peptide portion at C(1) or at C(2) of adamantyl moie-
ty)9,10 affect their immune reaction we were encouraged 
to synthesize the new unnatural amino acid of the ada-
mantane type for further structure-activity studies. Crys-
tal structure of ethyl adamant-2-ylidenecyanoacetate, 




The chemical reagents used in syntheses were obtained 
from Fluka and Aldrich Corp. All solvents were purified 
using standard procedures. Thin layer chromatography 
(TLC, solvents and proportions are given in the text) 
was performed on Fluka silica gel (60 F 254) plates 
(0.25 mm). Visualization was effected by use of UV 
light, iodine and ninhydrin. Melting points were deter-
mined in open capillaries using Büchi B-540 melting 
point apparatus and are uncorrected. IR spectra were 
recorded using Perkin Elmer FT-IR Spectrometer  
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Spectrum Two. 1H and 13C NMR spectra were recorded 
with Bruker Avance spectrometer at room temperature 
at 300 MHz and 75 MHz, respectively. Chemical shifts 
are given in ppm downfield from TMS as internal  
standard. Electrospray ionization mass spectrometry 
(ESI-MS) was performed using Agilent 6410 MS  
instrument. High resolution mass spectra (HRMS) were 
obtained by matrix-assisted laser desorption/ionization–
time-of-flight MALDI-TOF/TOF mass spectrometer 
(4800 Plus MALDI TOF/TOF analyzer, Applied  
Biosystems Inc., Foster City, CA, USA) equipped with 
Nd:YAG laser operating at 355 nm with firing rate  
200 Hz in the positive ion reflector mode.  
 
Synthesis 
Ethyl adamant-2-ylidenecyanoacetate (1) 
2-Adamantanone (1 g, 6.66 mmol) and ethyl 
cyanoacetate (0.71 mL, 6.66 mmol) were dissolved in 
dry benzene (20 mL). NH4OAc (0.10 g, 1.33 mol) and  
concentrated HOAc (1.05 mL, 5.33 mol) were then 
added. Reaction mixture was refluxed in Dean-Stark 
apparatus for 24 h. The mixture was diluted with  
benzene and extracted with water. The organic layer 
was concentrated under the reduced pressure giving 
yellow oil. 70 % EtOH (aq) was added and white solid 
precipitated from the solution after cooling. Recrystalli-
zation from ethanol/water gave colourless crystals  
(1.5 g, 91 %); Rf = 0.57 (petroleum ether/diethyl ether = 
2:1); m.p. 79–80 °C (lit. 81–82 °C).18 IR (KBr)  
max / cm–1: 2983, 2931, 2857 (C–H), 2221 (CN), 1725 
(C=O), 1593 (C=C). 1H NMR (CDCl3) δ / ppm: 4.27  
(q, 2H, J = 7.2 Hz, OCH2), 2.13–1.84 (m, 14H, Ad), 
1.36 (t, 3H, J = 7.1 Hz, CH3). 13C NMR (CDCl3): 
188.72 (CO), 162.14 (C=C, Ad), 115.53 (CN), 98.17 
(C=C(CN)COOEt), 61.56 (OCH2), 40.05, 39.66, 36.12 
(CH2, Ad), 40.09, 34.44, 27.18 (CH, Ad), 14.05 (CH3). 
ESI-MS: [M+H]+ m/z 246.4.  
 
Ethyl 2-(adamant-2-yl)-3-aminopropanoate (2) 
To a solution of compound 1 (200 mg, 0.82 mmol) in 
MeOH (15 mL) 10 % Pd/C (40 mg) and concentrated 
HCl (0.28 mL) were added. The mixture were subjected 
to hydrogen atmosphere under 40 PSI at room tempera-
ture and stirred for 6 h. Then the catalyst was filtered off 
and the filtrate concentrated under reduced pressure. 
The resulting oil was suspended in water and extracted 
with diethyl ether in order to remove the unreacted 
compound 1. The aqueous layer was then treated with  
2 M NaOH (pH 12), extracted with ethyl acetate and 
organic layers dried over anhydrous Na2SO4. After 
filtration, the organic layer was concentrated in vacuo 
and the product 2 (175 mg, 85 %) was obtained as a 
colourless oil. Rf = 0.45 (CHCl3/MeOH = 4:1). IR (KBr) max/cm–1: 3378, 3309 (N–H stretch), 2907, 2852 (C–H), 
1728 (C=O), 1599 (N–H bend). 
1H NMR (CDCl3): 4.22–4.12 (m, OCH2), 2.96–2.82  
(m, 3H, CH-α, CH2NH2), 2.03–1.52 (m, 17H, Ad, NH2), 
1.27 (t, 3H, J = 7.1 Hz, CH3). 13C NMR (CDCl3): 
175.72 (CO), 60.09 (OCH2), 50.30 (CH-α), 44.35 (CH, 
Ad), 42.25 (CH2NH2), 38.88, 38.09, 31.87, 31.53 (CH2, 
Ad), 30.95, 28.83, 27.94, 27.67 (CH, Ad), 14.35 (CH3). 
ESI-MS: [M+H]+ m/z 252.2.  
 
2-(Adamant-2-yl)-3-aminopropanoic acid (3) 
Compound 2 (70 mg, 0.28 mmol) was dissolved in a 1:2 
mixture of dioxane / 2 M NaOH (6 mL). Reaction  
mixture was stirred at room temperature for 48 h and 
monitored by TLC (CHCl3/MeOH = 4:1), Rf value of 
product 3 was 0.10. Reaction mixture was then treated 
with 2 M HCl (pH ~ 6) and product 3 precipitated as a 
white solid (56 mg, 90 %). m.p. 279–281 °C (decomp.); 
IR (KBr) max/cm–1: 3100–2300 (N–H stretch, H3N+), 
2901, 2848 (C–H), 1636 (N–H bend) 1579, 1401  
(COO–). HRMS: calcd. for C13H21NO2 [M+H]+: 
224.1645; found at m/z 224.1646. To obtain the NMR 
data compound 3 was converted into the water soluble 
hydrochloride form. Product 3 was suspended in water 
and treated with 2 M HCl (pH ~ 1). Aqueous solution 
was saturated with brine and extracted with ethyl  
acetate. After removal of solvent product 3 (in hydro-
chloride form) was isolated as a white solid contaminat-
ed with sodium chloride. IR (KBr) max/cm–1: 3300–
2500 (O–H, N–H stretch), 2909, 2865, 2848 (C–H), 
1726 (C=O), 1629, 1531 (N–H bends). 1H NMR (D2O) 
δ/ppm: 3.30–3.05 (m, 3H, CH-α, CH2NH2), 1.93–1.56 
(m, 15H, Ad). 13C NMR (D2O): 177.78 (CO), 44.94 
(CH-α), 43.91 (CH, Ad), 39.24 (CH2NH2), 38.21, 38.12, 
37.37, 31.19, 30.78 (CH2, Ad), 30.41, 28.41, 27.44, 
27.27 (CH, Ad). HRMS: calcd. for C13H21NO2 M+: 
224.1645; found at m/z 224.1644.  
 
X-ray Structural Analysis of 1 
Single crystals for X-ray analysis of 1 were obtained by 
recrystallization of the compound from a ethanol/water 
mixture. A suitable crystal was glued to a thin glass 
needle. The single-crystal X-ray diffraction data were 
collected at room temperature by –scans on an Oxford 
Diffraction Xcalibur 3 CCD diffractometer with graph-
ite-monochromated Mo-Kα radiation (λ = 0.71073 Å). 
The data reduction was performed using the CrysAlis 
software package.19 Solution, refinement and analysis of 
the structure was done using the programs integrated in 
the WinGX system.20 The structure was solved by direct 
methods using SIR97.21 The refinement procedure was 
performed by the full-matrix least-squares method based 
on F2 against all reflections with the program  
SHELXL-97.22 All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were placed in  
calculated positions and refined using the riding model. 
Geometry calculations were done using PLATON,23 
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while the structure drawings were prepared using 
PLATON and MERCURY24 programs. The crystallo-
graphic data are summarized in Table 1. 
 
RESULTS AND DISCUSSION 
 The precursor in the synthesis of adamantane-derived 
β-amino acid was ethyl adamant-2-ylidenecyanoacetate 
(1). Compound 1 was prepared by the condensation of  
2-adamantanone with ethyl cyanoacetate, according to 
Cope's procedure (Scheme 1) in excellent yield.25  
Compound 1 was previously used as the precursor in the 
synthesis of adamantane-based α-amino acid, (adamant-
2-yl)glycine, and it is also known as a precursor of 
adamantane spiro-3’-pyrrolidines which show antiviral 
acitivities.18 The crystal structure of ethyl adamant-2-
ylidenecyanoacetate (1) was determined and is  
described in this paper for the first time.  
 
X-ray Analysis of Ethyl Adamant-2-ylidenecyano-
acetate (1) 
The molecular geometry, as determined by X-ray analy-
sis, and the atom labelling scheme of 1 is shown in  
Fig. 1, while the unit cell packing is illustrated in Fig. 2. 
The selected bond distances and angles are given in 
Table 2. The values of bond distances and angles are 
similar to those found in other related compounds.26–29 
The molecular structure of 1 is characterized by 
adamantylidene and ethyl cyanoacetate moieties.  
The adamantane unit consists of four cyclohexa-
nes fused with each other, all approaching the ideal 
chair conformations. The Cambridge Structural Data-
Base, CSDB,30 search using the ConQuest Version 1.14, 
gave 34 structures containing the adamantylidene unit 
with the C=C double bond in the range of 1.319– 
1.441 Å. The C1=C11 double bond in 1 has a length of 
1.352(4) Å. Substitution at C1 has an influence on the 
C2–C1–C9 angle which is the largest one in the 
adamantne unit being 111.9(2)° and also on the C1–C2 
and C1–C9 bond lengths which are the shortes ones in 
that unit. Analysis of the structures from CSDB resulted 
in the range of 109.3° to 113.6° for the mentioned angle, 
with a mean value of 111.6° which is very close to the 
value found in 1. In the DataBase there are only 2 struc-
tures with a methylacetate substituent: two polymorphs 
of dimethyl 2,3-bis(tricyclo[3.3.1.13,7]dec-2-ylidene)-
butanedionate.28 There is only one structure having a 
cyano group as a substituent: in 2-adamanthylidene 
Figure 1. The molecular structure of 1. Displacement ellip-
soids are drawn at the 30 %. 
Table 1. Crystallographic data for compound 1  
Empirical formula C15H19NO2 
Mr 245.31 
T / K 293 
Crystal colour, habit colourless, prism 
Crystal size / mm3 0.12 × 0.24 × 0.46 
Crystal system Monoclinic 
Space group P 21/n 
Unit cell parameters  
a / Å 6.9823(4) 
b / Å 18.0046(10) 
c / Å 10.4542(7) 
β / ° 91.757(6) 
V / Å3 1313.62(14) 
Z 4 
Dcalc /g cm–3 1.240 
μ / mm–1 0.082 
F(000) 528 
Total data 8276 
Number of unique data 2273 
Number of data [Fo ≥ 4σ(Fo)] 1458 
Number of parameters 164 
R1(a), [Fo ≥ 4σ(Fo)] 0.0687 
wR2(b) 0.1781 
Goodness of fit on F2, S 1.04 
Min. and max. electron density / e Å–3 –0.38, 0.50 
(a) R = Σ║Fo│– │Fc││/ Σ│Fo│ 
(b) wR =  [Σ(Fo2 – Fc2)2 / Σw(Fo2)2]1/2 
 
Scheme 1. Preparation of ethyl adamant-2-ylidenecyano-
acetate (1). 
422 V. Petrović Peroković et al., Adamantane β-Amino Acid 
Croat. Chem. Acta 85 (2012) 419. 
malondinitrile there are two cyano groups on C11.31 In 1 
there is some electron delocalization effecting bonds 
C11–C12 and C11–C13 which are shortened in relation 
to a single bond, and also effecting bonds N1–C12 and 
C1–C11 which are slightly lengthened in relation to 
formal triple and double bonds, respectively. A similar 
delocalization was found in the above mentioned com-
pound where the authors attributed 10 % to this effect.  
There are no classical hydrogen bonds in the  
crystal structure. Weak intramolecular hydrogen bonds 
C9−H9O1 and C15−H15BO1 are present 
(d(C9O1)= 2.976(4) Å and d(C15O1)= 3.167(5) Å). 
The unit cell packing is controlled by a pair of weak 
intermolecular electrostatic C4−H4AN1 contacts  
connecting molecules into centrosimetical dimers at a 
C4−H4AN1[−x,−y,−z] distance of 3.478(4) Å. 
The crystal packing of the related compound28 also 
shows only weak intermolecular C−HO interactions. 
The knowledge of the structure of ethyl adamant-
2-ylidenecyanoacetate 1 may be useful for the  
prediction of the outcome of enantioselective syntheses 
of α- or β-amino acids. Furthermore, it can be useful in 
possible chemical modifications of compound 1 (reduc-
tions, hydrolysis or click-reactions) that could be  
utilized for the preparation of pharmaceutically interest-
ing compounds. 
 
Synthesis of the Adamantane β-Amino Acid (3) 
The efficient preparation of the novel adamantane-
containing β-amino acid is described in Scheme 2.  
Unsaturated cyanoester 1 was reduced to ethyl  
2-(adamant-2-yl)-3-aminopropanoate (2) by catalytic 
hydrogenation, using 10 % Pd/C catalyst in strong acid-
ic conditions (4 equivalents of concentrated HCl).  
Hydrogen pressure of 4 PSI at room temperature was 
appropriate for the reduction of the carbon-carbon  
double bond and the cyano group. Hydrochloric acid 
was added to prevent the generation of byproducts 
which could result if the product of reduction, primary 
amine (2), reacts with the intermediate imine. Under the 
given reaction conditions only traces of the unreacted 
cyanoester 1, and none of the possible byproducts, were 
observed by TLC monitoring. The reaction time was 
optimized and after 6 h a high yield (85 %) was 
achieved. Prolonged reaction time did not increase the 
yield. Unreacted compound 1 can be easily removed by 
extraction from the acidic reaction mixture and then re-
used. The resulting chemical transformation was con-
firmed by spectral data (MS, NMR and IR). The effica-
cy of reduction was clearly confirmed by the absence of 
the characteristic signals in IR and 13C NMR spectra 
belonging to the CN group and C=C bonds. 
Racemic amino acid 3, 2-(adamant-2-yl)-3-
aminopropanic acid, was obtained in high yield (90 %) 
after the saponification of the ester 2. Basic reaction 
mixture was treated with HCl (aq) to obtain the neutral 
β-amino acid. At pH ~ 6 compound 3 was in a zwitter-
ionic form, insoluble in water. IR and MS data support 
the structure of compound 3. The carboxylate ion of 
zwitterion 3 gives two typical bands in the IR spectra: a 
strong, asymmetrical stretching band at 1579 cm−1 and a 
Figure 2. The crystal packing of molecules in the unit cell.
Intramolecular C9−H9⋅⋅⋅O1 and C15−H15B⋅⋅⋅O1 and intermo-
lecular C4−4A⋅⋅⋅N1 contacts are shown by dashed lines. 
Table 2. The selected interatomic distances (Å) and angles (˚) 
for compound 1 
O1 − C13 1.195(4) 
O2 − C13 1.338(4) 
O2 – C14 1.511(5) 
N1 – C12 1.141(5) 
C1 – C2 1.502(4) 
C1 – C9 1.503(4) 
C1 – C11 1.352(4) 
C11 – C12 1.437(4) 
C11 – C13 1.485(4) 
C14 – C15 1.431(7) 
C13 – O2 – C14 117.4(3) 
C2 – C1 – C9 111.9(2) 
C2 – C1 – C11 122.6(2) 
C9 – C1 – C11 125.4(2) 
N1 – C12 – C11 179.2(3) 
O1 – C13 – O2 123.0(3) 
O1 – C13 – C11 127.2(3) 
O2 – C13 – C11 109.8(3) 
O2 – C14 – C15 104.7(4) 
C1 – C11 – C12 119.3(3) 
C1 – C11 – C13 125.8(3) 
C12 – C11 – C13 115.0 (2) 
O1 − C13 1.195(4) 
O2 − C13 1.338(4) 
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weaker, symmetrical stretching band at 1401 cm−1.  
A broad, strong NH3+ stretching band in the 3100− 
2300 cm−1 region also supports the zwitterionic structure 
of 3. To obtain the NMR data 3 was converted into the 
water soluble hydrochloride form. IR and NMR spectra 
of the hydrochloride displayed the expected signals. 
Therefore, the structure of the novel adamantane  
β-amino acid was undoubtedly confirmed. 
 
CONCLUSION 
Preparation and characterization of novel adamantane-
derived β-amino acid, 2-(adamant-2-yl)-3-aminoprop-
anic acid, is reported. The amino acid was synthesized 
in only three steps with very good overall yield (70 %). 
In the first step ethyl adamant-2-ylidenecyanoacetate (1) 
was prepared by the condensation of 2-adamantanone 
and ethyl cyanoacetate and its crystal structure was 
determined. Knowledge of this crystal structure can be 
useful in an enantioselective synthesis of adamantane  
α- or β-amino acids. Unsaturated cyanoester 1 was con-
verted to ethyl 2-(adamant-2-yl)-3-aminopropanoate (2). 
In the same step carbon-carbon bond and cyano group 
were efficiently reduced by catalytic hydrogenation in 
strong acidic conditions. The desired racemic amino 
acid was obtained after ester hydrolysis and it was fully 
characterized. The described amino acid will be used as 
a building block in the preparation of potentially biolog-
ically active peptides. 
Supplementary Materials. CCDC 888912 contains the  
supplementary crystallographic data for this paper. These data 
can be obtained free of charge via www.ccdc.cam.ac.uk/data 
request/cif, or by e-mailing to data request@ccdc.cam.ac.uk, 
or by contacting The Cambridge Crystallographic Centre, 12, 
Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 
336033.  
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